UBS Remains Bullish Following Baxalta's (BXLT) Solid 4Q Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Baxalta Posts Strong Fourth Quarter 2015 Sales and Earnings; Positive Momentum Continues with Achievement of Key Milestones
February 16, 2016 6:40 AM ESTResults reflect successful transition to a standalone company with compelling commercial, regulatory, clinical, operational and financial execution Broad and differentiated portfolio of leading hematology and immunology therapies driving sustainable growth and value Differentiated oncology portfolio augmented by pipeline progress and new, strategic immuno-oncology collaboration Significant advances toward delivering 20 new product launches by 2020 with key milestone achievements and FDA approvals of ADYNOVATE and VONVENDI
BANNOCKBURN, Ill.--(BUSINESS WIRE)-- Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader... More
